Skip to content
Search

Latest Stories

Wes Streeting pledges stability for community pharmacy amid financial pressures

Wes Streeting community pharmacy funding
Wes Streeting speaks at an evidence session by the Health and Social Care Committee on 18 December 2024

Health secretary Wes Streeting has pledged to stabilise the community pharmacy system before enabling it to take on a broader role in healthcare, as he addressed the Health and Social Care Select Committee in Parliament on Wednesday (18 December).

“Now that we have got the budget set, we will be consulting with Community Pharmacy England shortly in the New Year,” Streeting stated. “I do want to reassure pharmacists across the country that we are taking into account the enormous pressures they are under when thinking about allocations so that we can stabilise the system and create the foundations from which to recover.”


The health secretary emphasised that his top priority is to “stabilise the [community pharmacy] system” before expanding initiatives such as Pharmacy First and independent prescribing. He also expressed a vision for community pharmacies to play “a bigger role… as part of the shift from hospital to community,” but stressed that immediate steps are required to address the sector’s current financial strain.

The announcement that Community Pharmacy Contractual Framework (CPCF) negotiations will commence early in the New Year was reaffirmed by Streeting, echoing a statement made earlier in the week by minister for care Stephen Kinnock during a Westminster Hall debate.

Streeting further confirmed that he is working with the minister for care to devise a package that will “initially stabilise the system and create a more stable foundation from which to build a better future for pharmacy.”

During the committee session, Joe Robertson MP highlighted concerns over the impact of increased employer National Insurance contributions on NHS providers, citing Community Pharmacy England’s analysis that the proposed rise will cost community pharmacies £50m annually.

In response, Streeting acknowledged the “wide range of pressure” on the sector and assured that these factors are being considered in funding decisions.

Janet Morrison, chief executive of Community Pharmacy England, welcomed the recognition of the sector’s challenges but underscored the urgency of addressing its financial crisis. “Community pharmacy owners are in an absolutely desperate financial position and need urgent answers on funding,” she said. “I wrote to Ministers earlier this month to reiterate the very perilous position that the sector is in, and to warn of the serious consequences should the current chronic underfunding of the sector continue.”

Morrison added, “It has been encouraging this week to hear the Secretary of State recognising the immense pressures that the sector is under, and also Ministers noting the enormous amount of work that is going on in community pharmacies to support patients and communities. MPs from across the political spectrum have also been calling for the support and investment that pharmacies need.”

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less